Canadian Admits Selling Fake Cancer Drugs Online

The scammer faces up to 20 years in prison for wire fraud.

Thomas Claburn, Editor at Large, Enterprise Mobility

May 12, 2010

1 Min Read
Dark Reading logo in a gray background | Dark Reading

A 22-year-old Canadian man pleaded guilty on Tuesday in Phoenix, Arizona, to selling fake cancer drugs over the Internet.

Hazim Gaber, a resident of Edmonton, Canada, was indicted last year on five counts of wire fraud, according to the Department of Justice. He was arrested in Germany in 2009 and extradited to the U.S.

At his plea hearing, Gaber acknowledged selling what he claimed was the experimental cancer drug sodium dichloroacetate, or DCA, to at least 65 people in the Belgium, Canada, the Netherlands, the U.K., and the U.S.

Court documents state that "DCA is an odorless, inexpensive, relatively non-toxic experimental cancer drug that is highly sought after by cancer patients."

DCA is not approved by the FDA and is only available to patents in clinical trials.

What Gaber provided to customers, however, was not DCA. It was, he acknowledged, various common white powdery substances such as starch, dextrin, dextrose, or lactose.

A Department of Justice spokesperson did not immediately respond to a request for information about the extent to which the cancer patients who took the fake DCA suffered harm as a result of being duped.

Gaber also acknowledged that his Web site, DCAdvice.com, included false claims that the site was the only lawful supplier of DCA and that the site was affiliated with the University of Alberta.

The doctor who published the 2007 study that suggested DCA's effectiveness as a cancer treatment, Evangelos Michelakis, is a professor in the University's Department of Medicine.

In his plea, Gaber also admitted to selling more than 800 copies of pirated business software.

Gaber faces up to 20 years in prison and a fine of $250,000 for each count of wire fraud. His sentencing is scheduled for August 2.

About the Author

Thomas Claburn

Editor at Large, Enterprise Mobility

Thomas Claburn has been writing about business and technology since 1996, for publications such as New Architect, PC Computing, InformationWeek, Salon, Wired, and Ziff Davis Smart Business. Before that, he worked in film and television, having earned a not particularly useful master's degree in film production. He wrote the original treatment for 3DO's Killing Time, a short story that appeared in On Spec, and the screenplay for an independent film called The Hanged Man, which he would later direct. He's the author of a science fiction novel, Reflecting Fires, and a sadly neglected blog, Lot 49. His iPhone game, Blocfall, is available through the iTunes App Store. His wife is a talented jazz singer; he does not sing, which is for the best.

Keep up with the latest cybersecurity threats, newly discovered vulnerabilities, data breach information, and emerging trends. Delivered daily or weekly right to your email inbox.

You May Also Like


More Insights